Characterised autologous human cartilage cells 4million cells/0.4ml implantation suspension vials
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Characterised autologous human cartilage cells on the MHRA register
ChondroCelect 4million cells/0.4ml implantation suspension vials
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 26 · Randomised trials: 5 · 2002–2026
Showing the 50 most relevant studies, sorted by most relevant.
Liangjing Lu, Cheng-xiang Dai, Zhongwen Zhang, et al.
Stem Cell Research & Therapy, 2019
Khalid U, Uchikov P, Hristov B, et al.
2023
- Plastic Surgery Procedures
- Postoperative Period
- PubMed
Background and Objectives: The aim of this review is to explore the recent surgical innovations in tracheal reconstruction by evaluating the uses of synthetic material fabrication when dealing with tracheomalacia or stenotic pathologies, then discussing the challenges holding back these innovations. Materials and Methods: A targeted non-systematic review of published literature relating to tracheal reconstruction was performed within the PubMed database to help identify how synthetic materials are utilised to innovate tracheal reconstruction. Results: The advancements in 3D printing to aid synthetic material fabrication have unveiled promising alternatives to conventional approaches. Achieving successful tracheal reconstruction through this technology demands that the 3D models exhibit biocompatibility with neighbouring tracheal elements by encompassing vasculature, chondral foundation, and immunocompatibility. Tracheal reconstruction has employed grafts and scaffolds, showing a promising beginning in vivo. Concurrently, the integration of resorbable models and stem cell therapy serves to underscore their viability and application in the context of tracheal pathologies. Despite this, certain barriers hinder its advancement in surgery. The intricate tracheal structure has posed a challenge for researchers seeking novel approaches to support its growth and regeneration. Conclusions: The potential of synthetic material fabrication has shown promising outcomes in initial studies involving smaller animals. Yet, to fully realise the applicability of these innovative developments, research must progress toward clinical trials. These trials would ascertain the anatomical and physiological effects on the human body, enabling a thorough evaluation of post-operative outcomes and any potential complications linked to the materials or cells implanted in the trachea.
Abstract licence: CC BY
Caterino C, Della Valle G, Aragosa F, et al.
2023
Platelet concentrates (PCs) have become widely used in veterinary and human medicine. The PCs consist mainly of supraphysiological concentrations of platelets and, therefore, growth factors (GFs) which are stored within platelet α-granules. Among PCs, Platelet-Rich Plasma (PRP) is characterised by low-density fibrin. Research on the effect of PCs in cattle has surged in recent years; in particular, evidence has shown the positive use of PRP for treating reproductive problems, in vitro production of bovine embryos, sole ulcers and udder diseases. The aim of this report is to critically review, in accordance with the PRISMA guidelines, the available literature reporting clinical application in the bovine practice of PRP. Three bibliographic databases PubMed, Web of Science and Scopus were used for a broad search of "platelet concentrates" OR "PRP" OR "platelet-rich plasma" OR "PRF" OR "platelet-rich fibrin" AND "cows" OR "cattle". From 1196 papers, only six met the inclusion criteria. Two papers described the use of PRP in mastitis, two papers in uterine dysfunction and two papers in ovarian dysfunction. PRP offered a low-cost, easily obtained therapeutic option and showed positive results for these patients. However, given the different pathologies and definitions involved, further studies are necessary to assess its full clinical potential.
Abstract licence: CC BY
Fuenteslópez CV, Bahcevanci S, Patrulea V, et al.
2026
BackgroundFibrin is a biocompatible, angiogenic biomaterial widely used in soft tissue engineering, with outcomes influenced by scaffold formulation and design.AimThis systematic review evaluates how fibrin scaffold composition and design affect angiogenesis in in vitro and in vivo soft tissue models.MethodsPubMed, Scopus, and OVID were searched on 28/Oct/2024. A two-step screening process by three independent researchers identified original studies on fibrin scaffolds assessing endothelial formation and/or migration. Studies without experimental data or focused solely on grafts were excluded. Data on scaffold composition, manufactured objects, cell-embedding strategies, angiogenic outcomes, and a subset of muscle-specific studies were narratively synthesised. Risk of bias (RoB) and study quality were assessed using SYRCLE's RoB tool and a modified CAMARADES checklist.Results & discussionThe 81 studies highlight the impact of scaffold composition on angiogenic outcomes, with human-derived fibrinogen and pre-embedding cells consistently supporting successful outcomes. While tube and network formation outcomes typically aligned, endothelial migration exhibited different patterns. Thrombin often contributed positively, but crosslinker effects were less clear. Muscle-focused studies mainly used hydrogels and often included non-endothelial cells.ConclusionsFibrin scaffolds are highly relevant for soft tissue engineering, with outcomes influenced by formulation, fibrinogen source, and cell embedding. However, experimental design variability and lack of standardised reporting hinder reproducibility and clinical translation. To support future research, a minimum information checklist was created to promote consistent reporting, while aggregated success rates across design parameters could guide scaffold design.Registration & fundingPROSPERO [CRD42025612994] and OSF [10.17605/osf.io/nvfdj]. No funding body was directly involved.
Abstract licence: CC BY
Kohlhauser M, Lüttschwager S, Pignet AL, et al.
2026
- Adipose Tissue
- Stem Cells
- Cicatrix, Hypertrophic
A. Ruano-Ravina, M. Jato Díaz
Osteoarthritis and Cartilage, 2006
P. Vavken, D. Samartzis
Osteoarthritis and Cartilage, 2010
Chang Hee Woo, Harkkyun Kim, G. Jung, et al.
Journal of Extracellular Vesicles, 2020
Yang Song, Hui Du, Cheng-xiang Dai, et al.
Regenerative medicine, 2018
T. D. de Windt, L. Vonk, I. Slaper-Cortenbach, et al.
STEM CELLS, 2017
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.